VUDALIMAB

UNII:	4I9I5X3Z6N
Formula:
Preferred Substance Name:	VUDALIMAB
GSRS Full Record:	4I9I5X3Z6N i

2329669-72-7
ANTI-PD-1/ANTI-CTLA-4 XMAB20717
ANTI-PD1/CTLA4 BISPECIFIC ANTIBODY XMAB20717
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 SINGLE-CHAIN VARIABLE FRAGMENT VL-LINKER-VH) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (260->227'),(263->230')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN PROGRAMMED CELL DEATH 1) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 .KAPPA.-CHAIN
PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR XMAB20717
VUDALIMAB [INN]
VUDALIMAB [USAN]
VUDALIMAB [WHO-DD]
XMAB20717
XMAB-20717

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

VUDALIMAB

Synonyms and Mappings

Resources